Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21

HIBAOUI, Youssef, et al.

Abstract

Down syndrome (trisomy 21) is the most common viable chromosomal disorder with intellectual impairment and several other developmental abnormalities. Here, we report the generation and characterization of induced pluripotent stem cells (iPSCs) derived from monozygotic twins discordant for trisomy 21 in order to eliminate the effects of the variability of genomic background. The alterations observed by genetic analysis at the iPSC level and at first approximation in early development illustrate the developmental disease transcriptional signature of Down syndrome. Moreover, we observed an abnormal neural differentiation of Down syndrome iPSCs in vivo when formed teratoma in NOD-SCID mice, and in vitro when differentiated into neuroprogenitors and neurons. These defects were associated with changes in the architecture and density of neurons, astroglial and oligodendroglial cells together with misexpression of genes involved in neurogenesis, lineage specification and differentiation. Furthermore, we provide novel evidence that dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) on chromosome 21 likely [...]
Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21

Youssef Hibaoui1,2, Iwona Grad1, Audrey Letourneau2, M Reza Sailani2, Sophie Dahoun2, Federico A Santoni2, Stefania Gimelli2, Michel Guipponi2, Marie Françoise Pelte3, Frédérique Béna2, Stylianos E Antonarakis2,4,* & Anis Feki1,5,**

Abstract

Down syndrome (trisomy 21) is the most common viable chromosomal disorder with intellectual impairment and several other developmental abnormalities. Here, we report the generation and characterization of induced pluripotent stem cells (iPSCs) derived from monozygotic twins discordant for trisomy 21 in order to eliminate the effects of the variability of genomic background. The alterations observed by genetic analysis at the iPSC level and at first approximation in early development illustrate the developmental disease transcriptional signature of Down syndrome. Moreover, we observed an abnormal neural differentiation of Down syndrome iPSCs in vivo when formed teratoma in NOD-SCID mice, and in vitro when differentiated into neuroprogenitors and neurons. These defects were associated with changes in the architecture and density of neurons, astroglial and oligodendroglial cells together with misexpression of genes involved in neurogenesis, lineage specification and differentiation. Furthermore, we provide novel evidence that dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) on chromosome 21 likely contributes to these defects. Importantly, we found that targeting DYRK1A pharmacologically or by shRNA results in a considerable correction of these defects.

Keywords disease modelling; Down syndrome; DYRK1A; induced pluripotent stem cells; neurodevelopment

Subject Categories Genetics, Gene Therapy & Disease; Neuroscience

DOI 10.1002/emmm.201302848 | Received 4 April 2013 | Revised 11 November 2013 | Accepted 12 November 2013 | Published online 27 December 2013

Introduction

Down syndrome (DS) caused by a trisomy of chromosome 21 (HSA21), is the most common genetic developmental disorder, with an incidence of one in 800 live births. DS individuals show cognitive impairment, learning and memory deficits, arrest of neurogenesis and synaptogenesis, and early onset of Alzheimer’s disease (AD; Antonarakis et al, 2004; Lott & Dierssen, 2010). The detailed pathogenetic mechanisms by which the extra copy of HSA21 leads to the neurodevelopmental DS phenotype remain unknown. High-resolution mapping of rare, partial trisomies of HSA21 has provided evidence that several regions exist on HSA21 with various ‘dosage sensitive’ genes contributing to a given phenotype, which could also be modified by other genes on HSA21 and in the rest of the genome (Lyle et al, 2008; Korbel et al, 2009).

Several approaches have been used to study the pathogenesis of DS. Mouse aneuploidies have been engineered to model the various DS phenotypes; these models display some behavioral, anatomical and cellular abnormalities similar to human phenotypes (reviewed in Das & Reeves, 2011). Additionally, studies with post-mortem human DS brains have allowed the investigation of neuroanatomical abnormalities and the alterations that occur during brain development (Becker et al, 1991; Mito & Becker, 1993; Guidi et al, 2008). Moreover, in vitro culture of neural progenitor cells (NPCs) isolated from brain of DS patients were informative in dissecting the mechanisms underlying brain defects (Bahn et al, 2002; Esposito et al, 2008; Bhattacharyya et al, 2009; Lu et al, 2011). The discovery that pluripotent stem cells (PSCs) can be induced from human adult somatic cells by the introduction of few factors and their extensive similarities to embryonic stem cells (ESCs; Takahashi et al, 2007;
Yu et al., 2009) has provided new opportunities for investigation in human developmental biology and diseases. Recent studies have been successful in generating disease-specific induced pluripotent stem cells (iPSCs) from a variety of neurodevelopmental and neurodegenerative disorders (Park et al., 2008; Soldner et al., 2009; Brennand et al., 2011; Israel et al., 2012), providing excellent in vitro models for the pathophysiology and potential treatment of these disorders (Hibaoui & Feki, 2012).

In the present study, we have generated iPSCs from fetal fibroblasts of monzygotic twins discordant for trisomy 21: Twin-N-iPSCs for the normal iPSCs and Twin-DS-iPSCs for the iPSCs carrying the trisomy 21. The use of monzygotic twins has allowed us to study the effect of the supernumerary chromosome 21 without the biological ‘noise’ of the variation of the genome. We evaluated their multiligneage potentials in vivo by teratoma formation when iPSCs were injected intramuscularly into immunodeficient SCID mice. The DS pathogenesis was further investigated when iPSCs were induced to differentiate into neural progenitor cells (NPCs) and neurons. Furthermore, we used Twin-DS-iPSCs to validate candidate genes involved in the impairment of neurogenesis described in DS patients. Among the numerous protein coding genes of HSA21, Dual specificit tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) encodes a proline-directed serine/threonine and tyrosine kinase which plays pleiotropic roles in neurodevelopment and disease (Tejedor et al., 1995; Guimerà et al., 1996; Song et al., 1996; Becker et al., 1998; Tejedor & Hämmerle, 2011). Transgenic mice carrying an extra copy of Dyrk1A display neurodevelopmental delays, motor abnormalities, learning and memory deficits, and altered synaptic plasticity (Smith et al., 1997; Allafaj et al., 2001; Ahn et al., 2006). Based on these studies, we investigated the role of DYRK1A in Twin-DS-iPSC-derived NPCs and neurons, through its inhibition by pharmacological means or by short hairpin RNA silencing.

**Results**

**Generation of iPSCs from monzygotic twins discordant for trisomy 21**

Normal (Twin-N) and Down syndrome (Twin-DS) fetal fibroblasts were isolated from monzygotic twins discordant for trisomy 21 (Dahoun et al., 2008) and used to establish Twin-N-iPSCs and Twin-DS-iPSCs using OCT4, SOX2, KLF4 and c-MYC genes as previously described (Takahashi et al., 2007; Grad et al., 2011; Fig 1A and B). All iPSC lines expressed markers of pluripotent cells including NANOG, OCT4, TRA-1-60, TRA-1-81 and SSEA4 as demonstrated by immunofluorescence staining (Fig 1C) and showed alkaline phosphatase activity (supplementary Fig S1A). Quantitative (qRT-PCR) and non quantitative RT-PCR analysis demonstrated expression of selected endogenous pluripotent transcription factors including OCT4, SOX2, NANOG, LIN28 and ZFP42 (REXI) in the generated iPSCs in contrast with the parental fibroblasts (Fig 1D and supplementary Fig S1B). As expected for cells that have acquired a pluripotent state, transgene silencing was verified after initial expansion of around 10 passages of Twin-N-iPSCs and Twin-DS-iPSCs (supplementary Fig S1B). Moreover, as in hESC-H1, OCT4 and NANOG promoter regions of Twin-N-iPSCs and Twin-DS-iPSCs were found hypomethylated in comparison with their parental fibroblasts (Fig 1E).

**Transcriptome dysregulation of DS iPSCs**

These iPSCs were evaluated to confirm the disease-specific genotype of their parental somatic cells. As revealed by karyotype and array-based comparative genomic hybridization analysis, Twin-DS-iPSCs showed the characteristic trisomy 21 while Twin-N-iPSCs had a normal karyotype (Fig 2A and B). Then, whole transcriptome analysis using mRNA-Sequencing confirmed that the majority of HSA21 genes are indeed more expressed in the trisomic lines than the euploid lines (Fig 2C and supplementary Fig S2A) which is consistent with the overall up-regulation of HSA21 genes in individuals with DS (Antonarakis et al., 2004; Lott & Dierssen, 2010). Principal component analysis (PCA) showed that the first principal component (PC1) clearly discriminated the trisomic from the euploid samples, explaining most of the variance in the whole genome data (72%) and in the analysis of HSA21 genes (91%: Fig 2D and supplementary Fig S2B).

Differential expression analysis was performed using the statistical R packages EdgeR and DESeq. We considered the genes reported as being differentially expressed by both packages thereby obtaining a conservative list of 580 downregulated and 624 upregulated genes expressed in Twin-DS-iPSCs (Bonferroni-corrected P-value < 0.01; Fig 2E and supplementary Table S2). To further characterize the biological processes that might be affected in Twin-DS-iPSCs, we investigated the functional annotations associated with 1204 differentially expressed genes using DAVID (Database for Annotation, Visualization and Integrated Discovery). The gene ontology (GO) analysis of the 580 genes downregulated in Twin-DS-iPSCs revealed significant enrichment for genes involved in multiple developmental processes including embryonic development and morphogenesis, organ development and morphogenesis and system development. Among these genes, 96 genes were associated with nervous system-related terms and specifically with nervous system development, central and peripheral nervous system development, brain development, neurogenesis, generation of neurons, neuron differentiation and axonogenesis (Table 1 and supplementary Fig S4). The GO analysis also revealed enrichment for terms linked to cellular adhesion (i.e. biological adhesion, cell adhesion, cell-cell adhesion) and to the cadherin signalling pathway. Additionally, WNT signalling and cancer pathways were found associated with the list of downregulated genes. The GO analysis of the 624 genes upregulated in Twin-DS-iPSCs showed enrichment for functions related to the regulation of RNA metabolic processes, regulation of transcription and DNA-dependent transcription. Interestingly, an important number of zinc finger protein genes were upregulated in Twin-DS-iPSCs (Table 1 and supplementary Table S3).

**In vivo and in vitro differentiation of normal and DS iPSCs**

To document their developmental potential in vivo, iPSCs were injected intramuscularly into immunodeficient SCID mice. Histological analysis revealed that Twin-N-iPSCs formed teratoma with all embryonic germ layers: mesoderm, ectoderm and endoderm (Fig 3A upper panel and supplementary Fig S4). In contrast, injection of Twin-DS-iPSCs formed teratoma with multiple cysts which were surrounded by an abundant undifferentiated mesenchyme (Fig 3A lower panel). Mucinous intestinal-type differentiation or foci of bone
were also found (Fig 3A lower panel). Surprisingly, differentiated ectoderm germ structures were not found in Twin-DS-iPSC-derived teratomas (Fig 3A lower panel). These results were confirmed by the near absence of staining for the neuroepithelial marker NESTIN in Twin-DS-iPSC-derived teratoma (supplementary Fig S4). We next determined that these iPSCs could differentiate in vitro into all three embryonic germ layers as detected by expression of the ectodermal marker β3-TUBULIN, the mesodermal marker α-SMOOTH MUSCLE ACTIN (α-SMA) and the endodermal marker α-FETOPROTEIN (AFP; Fig 3B).

Proliferation deficit and increased apoptosis in NPCs derived from DS iPSCs

IPSC lines were also characterized to confirm their differentiation potentials into neural progenitor cells (NPCs, day 21) in vitro through the protocol outlined in Fig 4A. As expected, the expression of the pluripotency markers OCT4 and NANOG decreased in both iPSCs when induced to differentiate into NPCs (Fig 4B). Under these conditions, we next investigated the kinetics of emergence of neuronal and non-neuronal markers in these cells. Interestingly, our

Figure 1. Normal and DS iPSCs exhibit markers of pluripotency.

A Schematic representation of Twin-N and Twin-DS parental fibroblasts reprogramming into Twin-N-iPSCs and Twin-DS-iPSCs using OCT4, SOX2, KLF4 and c-MYC genes

B Phase contrast images of Twin-N-iPSCs and Twin-DS-iPSCs growing on feeder cells.

C Immunofluorescence staining of Twin-N-iPSC and Twin-DS-iPSC lines for pluripotency markers NANOG, OCT4, SSEA4, TRA1-60 and TRA1-80.

D qRT-PCR of pluripotency-related genes; NANOG, OCT4, SOX2, LIN28 and ZFP42 (REX1). Data are represented as mean ± s.e.m. from n = 3.

E DNA methylation profile of OCT4 and NANOG promoters. The global percentage of methylated cytosines (% Me) is indicated (open and closed circles indicate unmethylated and methylated CpGs, respectively).
Figure 2. Whole genome and chromosome 21 triplication status.

A Karyotypes of Twin-N-iPSCs and Twin-DS-iPSCs are 46, XX and 47, XX+21, respectively.

B Ideogram and array-CGH profile showing the gain of one DNA copy of chromosome 21 in Twin-DS-iPSCs in comparison with Twin-N-iPSCs.

C Comparison of the normalized gene expression levels mean of log2 RPKM between Twin-N-iPSCs and Twin-DS-iPSCs (HSA21 genes are shown in red and the rest of the genome in blue).

D Principal component analysis (PCA) plot based on the normalized expression values in Twin-N-iPSCs and Twin-DS-iPSCs. The percentages represent the proportion of variance explained by each component.

E Heat map of the normalized gene expression values in Twin-DS-iPSCs and Twin-N-iPSCs for the 1204 differentially expressed genes. A negative z-score (in red) indicates low expression (below the mean) whereas a positive z-score (in green) shows high expression (above the mean). Diagram showing the proportion of genes differentially expressed between Twin-N-iPSCs and Twin-DS-iPSCs. See also supplementary Table S2.
results showed that NPCs derived from Twin-DS-iPSCs expressed more AFP than those derived from Twin-N-iPSCs (Fig 4C). In contrast, we did not find any difference in the expression of the endodermal marker GATA4 and the mesodermal markers SMA and T (Fig 4C and D). Moreover, the expression of the neuroepithelial precursor marker NES and the neuronal markers TUBB3, MAP2 and FOXA2 were lower in NPCs derived from Twin-DS-iPSCs than those derived from Twin-N-iPSCs (Fig 4E). In addition, Twin-DS-iPSC-derived cells exhibited a more astroglial phenotype as revealed by the greater expression of GFAP, S100B and VIM (Fig 4F). Also, we detected an increased expression of the basic helix-loop-helix transcription factors and oligodendroglial markers OLIG1 and OLIG2 in Twin-DS-iPSC-derived NPCs (Fig 4F).

To test whether the neurogenesis defect is associated with a decrease of NPC population in DS neurospheres, we analyzed the number of NESTIN and SOX2 double positive cells in dissociated neurospheres derived from Twin-N-iPSCs and Twin-DS-iPSCs. Importantly, we found a significant decrease of NESTIN/SOX2 double positive cells in Twin-DS-iPSC-derived NPCs (88.9 ± 3.8 versus 56.4 ± 2.9%, P < 0.0001 for neurospheres derived from Twin-N-iPSCs and Twin-DS-iPSCs, respectively; Fig 4G), indicating a reduced number of NPCs in Twin-DS-iPSC-derived neurospheres. Further analysis revealed an increased proportion of committed astroglial cells (2.4 ± 0.6 versus 13.0 ± 1.6%, P = 0.0009 for GFAP+ cells in neurospheres derived from Twin-N-iPSCs and Twin-DS-iPSCs, respectively) and oligodendroglial cells (3.7 ± 2.0 versus 11.7 ± 0.9%, P = 0.0055 for OLIG2+ cells in neurospheres derived from Twin-N-iPSCs and Twin-DS-iPSCs, respectively) in neurospheres derived from Twin-DS-iPSCs (supplementary Fig S5B). The proportion of committed neuronal cells had a tendency to be higher in neurospheres derived from Twin-DS-iPSCs but failed to reach significance (5.6 ± 0.9 versus 14.7 ± 3.6%, P = 0.089 for β3-TUBULIN+ cells in neurospheres derived from Twin-N-iPSCs and Twin-DS-iPSCs, respectively; supplementary Fig S5B). Next, we assessed whether the defective neurogenesis in DS is due to proliferation deficits and/or increased cell death of NPCs. As shown in Fig 3H, the proportion of Ki-67 positive cells is significantly lower in Twin-DS-iPSC-derived NPCs consistent with a reduced proliferation of Twin-DS-iPSC-derived NPCs. Moreover, NPCs derived from Twin-DS-iPSCs showed an approximately threefold increase of the number of apoptotic nuclei together with an approximately twofold increase of caspase-3 activity compared with those derived from Twin-N-iPSCs (Fig 4I and J). This proliferation deficit and increased apoptosis affected principally NESTIN positive cells as revealed by an approximately twofold decrease of the number of cells double positive for NESTIN and Ki-67 and an approximately four- and six-fold increase of the number of cells double positive for NESTIN and cleaved caspase-3 in neurospheres derived from Twin-DS-iPSCs (supplementary Figs S6 and S7).

**Altered maturation of NPCs derived from DS iPSCs into neurons**

When NPCs were further induced to mature into neurons, we found a decreased expression of β3-TUBULIN and MAP2, and an increase of GFAP, VIMENTIN, S100B, OLIG1 and OLIG2 markers in Twin-DS-iPSC-derived cells when compared with Twin-N-iPSC-derived cells, as revealed by immunofluorescence staining and qRT-PCR (Fig 5A and B). These results strongly support an impaired neurogenesis together with a shift from neuronal to astroglial and oligodendroglial phenotype in Twin-DS-iPSC-derived cells. Notably, this shift was still observed even when a greater number of NPCs was induced to mature into neurons which rules out the possibility that the reduced number of NPCs derived from Twin-DS-iPSCs could lead to the observed shift from neuronal to astroglial and oligodendroglial phenotype (unpublished observations). Quantification of neurite (either axons or dendrites) branching from soma of β3-TUBULIN positive neurons showed that the mean number of branches was approximately twofold lower in neurons derived from Twin-DS-iPSCs than those derived from Twin-N-iPSCs (Fig 5C). Thus, neurons derived from Twin-DS-iPSCs demonstrated reduced length of neurites (Fig 5D).

An impaired synaptic maturation together with an imbalance between excitatory and inhibitory synapses have been proposed to explain the cognitive impairment in DS (Kleschevnikov et al, 2004; Belichenko et al, 2007; Chakrabarti et al, 2007; Martinez-Cue et al, 2013). Therefore, we investigated the expression of both pre- and post-synaptic markers in neurons by immunofluorescence staining and qRT-PCR analysis. MAP2-positive dendrites in neurons derived from Twin-DS-iPSCs exhibited a reduced density of SYNAPSIN punctae (Fig 5E) and a reduced expression of SYN1 and SNAP25 transcripts (Fig 5F). We next investigated the proportion of GABA-ergic and glutamatergic neurons derived from Twin-N-iPSCs and Twin-DS-iPSCs. Interestingly, we found a reduced density of PSD95, a post-synaptic protein expressed in glutamatergic neurons and a lower expression of PSD95 transcripts in neurons derived from Twin-DS-iPSCs (Fig 5F and G). In contrast, we found a greater expression of GAD67 (which encodes an enzyme responsible for the synthesis of GABA in neurons) in Twin-DS-iPSC-derived neurons (Fig 5G). The expression of GAD67 protein had a tendency to be higher in neurons derived from Twin-DS-iPSCs but failed to reach significance (Fig 5F).

**Rescue of neurogenesis impairment of NPCs and neurons derived from DS iPSCs through Dyrk1a inhibition**

Considering that Dyrk1a is involved in neurodevelopment and altered in DS (Tejedor et al, 1995; Guimera et al, 1996; Song et al, 1996; Tejedor & Hämmerle, 2011), we investigated the role of Dyrk1a in NPCs and neurons derived from Twin-DS-iPSCs. As shown in Fig 6A, an approximately twofold increase of Dyrk1a protein was found in Twin-DS-iPSC-derived NPCs (see also supplementary Fig S8). Moreover, treatment of Twin-DS-iPSCs during neural induction into NPCs with the selective Dyrk1a inhibitor DYRK1A inhibitor epigallocatechine gallate (EGCG, 10 μM) resulted in a significant inhibition of Dyrk1a activity which reached almost the value of control (Fig 6B and C). Therefore, we tested whether Dyrk1a inhibition by EGCC treatment during neural induction and neuronal differentiation of Twin-DS-iPSCs, can affect the defective neurogenesis of these cells. Notably, EGCC treatment improved the number of NPCs derived from Twin-DS-iPSCs by promoting proliferation and preventing apoptosis (Fig 6D–F). To provide additional support for the role of Dyrk1a in these defects and to exclude a possible antioxidant effect of EGCC, knockdown of Dyrk1a was achieved using short hairpin RNA (shRNA) in Twin-DS-iPSCs (Fig 6G–I and supplementary Fig S6). Importantly, this knockdown improved the number of NPCs derived from Twin-DS-iPSCs by promoting proliferation and preventing apoptosis (Fig 6J–L). When these NPCs were further...
induced to mature into neurons, DYRK1A inhibition through EGCG treatment or shRNA improved the expression of the neuronal markers β3-TUBULIN and MAP2, indicative of an improvement of neurogenesis (Fig 7A–D).

To explore the possible mechanisms underlying these improvements, we further investigated the expression of crucial genes and pathways involved in neural fate and differentiation namely REST/NRSF (Kuwabara et al., 2004; Ballas et al., 2005), WNT and NOTCH

Table 1. Gene ontology (GO) categories of biological processes in which significant differentially expressed genes were grouped

<table>
<thead>
<tr>
<th>Category</th>
<th>Term</th>
<th>Count</th>
<th>%</th>
<th>P-value</th>
<th>Benjamini</th>
</tr>
</thead>
<tbody>
<tr>
<td>GO:0007275</td>
<td>Multicellular organismal development</td>
<td>189</td>
<td>33.6</td>
<td>1.10E-29</td>
<td>2.40E-26</td>
</tr>
<tr>
<td>GO:0048731</td>
<td>System development</td>
<td>165</td>
<td>29.3</td>
<td>1.60E-28</td>
<td>1.70E-25</td>
</tr>
<tr>
<td>GO:0032502</td>
<td>Developmental process</td>
<td>195</td>
<td>34.6</td>
<td>3.20E-27</td>
<td>2.30E-24</td>
</tr>
<tr>
<td>GO:0048856</td>
<td>Anatomical structure development</td>
<td>170</td>
<td>30.2</td>
<td>6.20E-27</td>
<td>3.40E-24</td>
</tr>
<tr>
<td>GO:0009653</td>
<td>Anatomical structure morphogenesis</td>
<td>103</td>
<td>18.3</td>
<td>8.20E-23</td>
<td>3.60E-20</td>
</tr>
<tr>
<td>GO:0007399</td>
<td>Nervous system development</td>
<td>95</td>
<td>16.9</td>
<td>2.30E-21</td>
<td>8.20E-19</td>
</tr>
<tr>
<td>GO:0048513</td>
<td>Organ development</td>
<td>125</td>
<td>22.2</td>
<td>3.40E-21</td>
<td>1.00E-18</td>
</tr>
<tr>
<td>GO:0032501</td>
<td>Multicellular organismal process</td>
<td>222</td>
<td>39.4</td>
<td>3.40E-21</td>
<td>9.30E-19</td>
</tr>
<tr>
<td>GO:0030154</td>
<td>Cell differentiation</td>
<td>117</td>
<td>20.8</td>
<td>1.70E-19</td>
<td>4.20E-17</td>
</tr>
<tr>
<td>GO:0048869</td>
<td>Cellular developmental process</td>
<td>118</td>
<td>21</td>
<td>1.50E-18</td>
<td>3.30E-16</td>
</tr>
<tr>
<td>GO:0007156</td>
<td>Homophilic cell adhesion</td>
<td>30</td>
<td>5.3</td>
<td>1.80E-17</td>
<td>3.60E-15</td>
</tr>
<tr>
<td>GO:002610</td>
<td>Biological adhesion</td>
<td>68</td>
<td>12.1</td>
<td>1.90E-17</td>
<td>3.40E-15</td>
</tr>
<tr>
<td>GO:0007155</td>
<td>Cell adhesion</td>
<td>67</td>
<td>11.9</td>
<td>6.60E-17</td>
<td>1.90E-14</td>
</tr>
<tr>
<td>GO:0016337</td>
<td>Cell-cell adhesion</td>
<td>41</td>
<td>7.3</td>
<td>9.70E-17</td>
<td>1.70E-14</td>
</tr>
<tr>
<td>GO:0009887</td>
<td>Organ morphogenesis</td>
<td>54</td>
<td>9.6</td>
<td>1.50E-13</td>
<td>2.20E-11</td>
</tr>
<tr>
<td>GO:0007389</td>
<td>Pattern specification process</td>
<td>36</td>
<td>6.4</td>
<td>2.20E-13</td>
<td>3.00E-11</td>
</tr>
<tr>
<td>GO:0009888</td>
<td>Tissue development</td>
<td>59</td>
<td>10.5</td>
<td>2.40E-13</td>
<td>3.10E-11</td>
</tr>
<tr>
<td>GO:0001501</td>
<td>Skeletal system development</td>
<td>39</td>
<td>6.9</td>
<td>4.20E-13</td>
<td>5.10E-11</td>
</tr>
<tr>
<td>GO:0009790</td>
<td>Embryonic development</td>
<td>53</td>
<td>9.4</td>
<td>7.50E-13</td>
<td>8.50E-11</td>
</tr>
<tr>
<td>GO:0048598</td>
<td>Embryonic morphogenesis</td>
<td>37</td>
<td>6.6</td>
<td>2.90E-12</td>
<td>3.10E-10</td>
</tr>
<tr>
<td>GO:0022008</td>
<td>Neurogenesis</td>
<td>52</td>
<td>9.2</td>
<td>2.20E-11</td>
<td>2.30E-09</td>
</tr>
<tr>
<td>GO:0043009</td>
<td>Chordate embryonic development</td>
<td>37</td>
<td>6.6</td>
<td>2.60E-11</td>
<td>2.60E-09</td>
</tr>
<tr>
<td>GO:0009792</td>
<td>Embryonic development ending in birth or egg hatching</td>
<td>37</td>
<td>6.6</td>
<td>3.40E-11</td>
<td>3.20E-09</td>
</tr>
<tr>
<td>GO:0048699</td>
<td>Generation of neurons</td>
<td>48</td>
<td>8.5</td>
<td>1.90E-10</td>
<td>1.80E-08</td>
</tr>
<tr>
<td>GO:0006357</td>
<td>Regulation of transcription from RNA polymerase II promoter</td>
<td>56</td>
<td>9.9</td>
<td>2.70E-10</td>
<td>2.40E-08</td>
</tr>
<tr>
<td>GO:0050793</td>
<td>Regulation of developmental process</td>
<td>52</td>
<td>9.2</td>
<td>1.30E-09</td>
<td>1.10E-07</td>
</tr>
<tr>
<td>GO:0051239</td>
<td>Regulation of multicellular organismal process</td>
<td>63</td>
<td>11.2</td>
<td>3.80E-09</td>
<td>3.10E-07</td>
</tr>
<tr>
<td>GO:0030182</td>
<td>Neuron differentiation</td>
<td>39</td>
<td>6.9</td>
<td>5.10E-09</td>
<td>3.90E-07</td>
</tr>
</tbody>
</table>

The table lists the biological processes that might be affected due to trisomy 21. GO categories are ranked by P-values and Benjamini-corrected P-values given by DAVID (see also supplementary Table S3). The number of genes differentially expressed in each category is also shown.
signalling pathways (Ciani & Salinas, 2005; Ables et al., 2011). Consistent with a previous report (Canzonetta et al., 2008), qRT-PCR clearly showed that REST/NRSF expression was reduced by approximately 30% in Twin-DS-iPSC-derived NPCs in comparison with Twin-N-iPSC-derived NPCs (Fig 7E). Moreover, we investigated the expression of NOTCH1 and NOTCH2 receptors, the NOTCH ligand DLL1 and the NOTCH target HES1. As shown in Fig 7E, NPCs derived from Twin-DS-iPSCs exhibited a 2.9- and 2.1-fold reduction of NOTCH1 and NOTCH2 respectively, as well as an approximately twofold reduction of DLL1 and HES1, in comparison with those derived from Twin-N-iPSCs. Similarly, the near absence of expression of WNT7A in NPCs derived from Twin-DS-iPSCs resulted in a 28-fold reduction of it expression compared to those derived from Twin-N-iPSCs (Fig 7E). Thus, WNT7B was also found downregulated in these cells (Fig 7E). Importantly, restoring DYRK1A expression in Twin-DS-iPSC-derived NPCs to near normal levels by shRNA, promoted the expression of these genes (Fig 7E).

**Discussion**

A major challenge in the field of DS research has been to recapitulate the disease features and to understand the molecular mechanisms by which the extra copy of HSA21 genes leads to the abnormalities observed in DS patients. Many attempts have been made to identify HSA21 genes involved in the cognitive impairment in DS patients. For instance, several studies reported genotype-phenotype correlations in DS using genetic analysis (Lyle et al., 2008; Korbel et al., 2009); however, the molecular mechanisms underlying most of the DS phenotypes remain unknown. In order to recapitulate the disease
Figure 4.
phenotype *in vitro*, both ESCs and iPSCs have been derived from embryos and patients with DS (Park et al, 2008; Biancotti et al, 2010; Shi et al, 2012). Shi et al reported a PSC model of AD pathology using DS iPSCs. Neurons derived from DS iPSCs exhibited greater secretion of amyloid peptides, tau protein phosphorylation and cell death, supporting the notion that DS iPSCs are an excellent model for AD study (Shi et al, 2012). To our best knowledge, our study is the first demonstrating a neurodevelopmental phenotype in human iPSC-derived neural population. Twin-N-iPSCs and Twin-DS-iPSCs were derived from monozygotic twins discordant for trisomy 21 and thus confounding effects from genomic variability were theoretically eliminated. Twin monozygosity and discordance for trisomy 21 abnormality were tested by cytogenetic, genotyping and BAC-array analysis in the case-report published by Dahoun and colleagues (Dahoun et al, 2008). Since the rest of the genome is identical between the two samples, we hypothesized that these twins were ideal to study the effect of the supernumerary HSA21.

Several observations and findings arise from the current study investigating the cellular and molecular characteristics of neural cells derived from Twin-DS-iPSCs. In this regard, transcriptional profiling has proven extremely informative for the study of many diseases (Brennand et al, 2011; Israel et al, 2012). First, the genetic profiling of Twin-DS-iPSCs confirms that trisomy 21 not only affected the expression of trisomic genes but also the expression of disomic genes in Twin-DS-iPSCs, which is consistent with the argument that trisomy 21 leads to the alteration of whole transcriptome (Lytle et al, 2008). Among these genes, we identified 96 downregulated genes related to brain-related functions (supplementary Fig S4). Then, network analysis further implicates several expected and new pathways involving developmental processes (including those related to neurogenesis), cancer pathways, regulation of transcription, zinc finger (Znf)-C2H2 type genes and cadherins (Fig 2F, Table S3 and supplementary Fig S5). Furthermore, network analysis of NPCs from Twin-N-iPSCs and Twin-DS-iPSCs (arrows, Hoechst 33342 staining).

Representative AMC fluorescence traces and quantification of caspase-3 activity in NPCs derived from Twin-N-iPSCs and Twin-DS-iPSCs. Data are represented as mean ± s.e.m. ***P < 0.001 by Students t-test from n > 4. See also supplementary Fig S7.

**Figure 4. In vitro differentiation of normal and DS iPSCs into neural progenitor cells.**

A. Schematic representation of neuroinduction of the iPSCs into NPCs and neuronal differentiation into neurons.

B-F qRT-PCR analysis of pluripotency, endodermal and mesodermal markers upon neural induction of Twin-N-iPSCs and Twin-DS-iPSCs into NPCs. The expression of neuronal, astroglial and oligodendrogial markers is also shown. Data are represented as mean ± s.e.m. For clarity, statistics are only shown at the NPC level (day 22). *ns non significant, *P < 0.05, **P < 0.01 by Students t-test from n = 3−5.

G. Proportion of SOX2/NESTIN double positive cells in NPCs derived from Twin-N-iPSCs and Twin-DS-iPSCs. See also supplementary Fig S5.

H. Cell proliferation analysis by Ki-67 staining of NPCs derived from Twin-N-iPSCs and Twin-DS-iPSCs. See also supplementary Fig S6.

I. Nuclear damage analysis of NPCs from Twin-N-iPSCs and Twin-DS-iPSCs (arrows, Hoechst 33342 staining).

J. Representative AMC fluorescence traces and quantification of caspase-3 activity in NPCs derived from Twin-N-iPSCs and Twin-DS-iPSCs. Data are represented as mean ± s.e.m. ***P < 0.001 by Students t-test from n > 4. See also supplementary Fig S7.
neurons differentiated from fetal DS NPCs (Bahn et al, 2013). Quantitative studies on brain of DS patient (Becker et al, 2002) derived from Twin-DS-iPSCs which is consistent with previous morphometric studies on brain of other DS patients (Shi et al, 2003). Anomalies in neuronal maturation observed in DS patients (Youssef Hibaoui et al, 2013a), 2012). In line with this, we present evidence that neurons derived from Twin-DS-iPSCs exhibit a synaptic phenotype similar to that observed in DS patients and in mouse models of DS (Becker et al, 1991; Dierssen et al, 2003; Chakrabarti et al, 2007). Neurons derived from Twin-DS-iPSCs exhibit a reduced density of SYNAPSIN punctae. Considering the key role of the pre-synaptic proteins such as SYNAPSIN, SNAP25 in the regulation of transmitter release, their reduced expression may alter synaptic function in neurons derived from Twin-DS-iPSCs. Moreover, excess inhibitory synapses at the expense of excitatory ones has been proposed to explain the abnormal synaptic plasticity in mouse models of DS (Kleschevnikov et al, 2014).
Figure 6. DYRK1A inhibition improves proliferation and prevents apoptosis of NPCs derived from DS iPSCs.

A Expression and activity of DYRK1A in NPCs derived from Twin-N-iPSCs and Twin-DS-iPSCs. Data are represented as mean ± s.e.m. **P < 0.01 by Students t-test from n = 4.

B Schematic representation for generation of NPCs from Twin-DS-iPSCs after incubation with EGCG 10 μM.

C Activity of DYRK1A in NPCs derived from Twin-N-iPSCs and Twin-DS-iPSCs. The effect of 10 μM EGCG is also shown. Data are represented as mean ± s.e.m. **P < 0.01, ***P < 0.001 by one-way ANOVA followed with Tukeys test from n = 5.

D–F Effect of DYRK1A inhibition by EGCG on the number (in D), the proliferation (in E, Ki-67 staining) and cell death (in F, caspase-3 activity) of NPCs derived from Twin-DS-iPSCs. Data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01 by one-way ANOVA followed with Tukeys test from n = 4.

G Schematic representation for generation of NPCs from Twin-DS-iPSCs after transduction with lentiviruses encoding shRNAs targeting DYRK1A.

H–L Expression (in H) and activity (in I) of DYRK1A in NPCs derived from Twin-N-iPSCs, Twin-DS-iPSCs and Twin-DS-iPSCs with DYRK1A shRNA. Effect of DYRK1A inhibition by shRNA on the number (in J), the proliferation (in K, Ki-67 staining) and cell death (in L, caspase-3 activity) of NPCs derived from Twin-DS-iPSCs. Data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA followed with Tukeys test from n = 4.
Figure 7.

EMBO Molecular Medicine  Neurevelopmental defect in DS iPSCs and rescue by DYRK1A Youssef Hibaoui et al

© 2013 The Authors

Figure 7.

EMBO Molecular Medicine  Neurevelopmental defect in DS iPSCs and rescue by DYRK1A Youssef Hibaoui et al

© 2013 The Authors

Figure 7.

EMBO Molecular Medicine  Neurevelopmental defect in DS iPSCs and rescue by DYRK1A Youssef Hibaoui et al

© 2013 The Authors

Figure 7.

EMBO Molecular Medicine  Neurevelopmental defect in DS iPSCs and rescue by DYRK1A Youssef Hibaoui et al

© 2013 The Authors

Figure 7.

EMBO Molecular Medicine  Neurevelopmental defect in DS iPSCs and rescue by DYRK1A Youssef Hibaoui et al

© 2013 The Authors

Figure 7.
DYRK1A result in neurodevelopmental defects. et al, 1996; Song, 2007; Ahn, 2006; Das & Reeves, 2011; Martinez de Lagran, 2012). The present study provides novel evidence that DYRK1A overexpression promotes quiescence and senescence through DREAM (DP, RB, E2F and MuvB) complex assembly, a complex involved in cell cycle processes (Litovchick et al, 2011).

Contrary to the numerous reported roles of DYRK1A in the control of cell cycle, very little is known regarding its impact on cell death. For instance, DYRK1A has been shown to prevent the intrinsic apoptotic pathway through the phosphorylation of caspase-9 during retina development (Laguna et al, 2008). In contrast, the overexpression of DYRK1A makes rat embryonic hippocampal progenitor cells more susceptible to apoptosis by phosphorylating and activating p53 which leads to the subsequent upregulation of p53 target genes and proteins such as FAS (Park et al, 2010). This is of special interest as the protein levels of the pro-apoptotic genes p53 and FAS are increased in the cerebral cortex and the cerebellum of DS patients (de la Monte et al, 2008; Seidl et al, 1999). In the present study, we provide novel evidence that the increased expression and activity of DYRK1A is responsible for the greater susceptibility to apoptosis of NPCs derived from TWIN-DS-iPSCs. Reducing DYRK1A expression and activity to near control values prevented the apoptosis of these cells. It remains to be established whether p53 and FAS are responsible for the increase in apoptosis induced by DYRK1A overexpression in NPCs derived from TWIN-DS-iPSCs.

Another important observation is that DYRK1A inhibition by shRNA increased the number of neurons derived from TWIN-DS-iPSCs. Consistent with a previous study (Canzonetta et al, 2008), this effect was associated with an increase of the expression of REST/NRSF, a transcription factor that activates genes encoding fundamental functions during neuronal differentiation including neural lineage specification, synapse formation and function (Kuwabara et al, 2004; Ballas et al, 2005; Abrajano et al, 2009). In this regard, the downregulation of REST/NRSF in fetal DS NPCs has been shown to lead to the subsequent downregulation of important regulators of cell adhesion and synaptic plasticity (Bahn et al, 2002). In agreement with this report, we found a reduced expression inhibits proliferation and induces premature neuronal differentiation of NPCs (Yabut et al, 2010). They showed that Dyrk1A overexpression through in utero electroporation inhibits neuronal cell proliferation in the embryonic neocortex. This effect was mediated by the nuclear export and degradation of cyclin D1, a cyclin required for cell proliferation by allowing the entry to the S phase (Yabut et al, 2010). More recently, Hämmerle and colleagues showed that Dyrk1A promotes cell cycle exit through induction of the expression of the cyclin-dependent kinase inhibitor p27kip1 in neural precursors, which further binds to and inhibits the cyclin/cyclin-dependent kinase complex that controls G1/S transition (Hämmerle et al, 2011). Moreover, Litovchick and colleagues demonstrated that Dyrk1A plays an important role in suppression of mammalian cell proliferation. In particular, Dyrk1A overexpression promotes quiescence and senescence through DREAM (DP, RB, E2F and MuvB) complex assembly, a complex involved in cell cycle processes (Litovchick et al, 2011).
of REST/NRSF in NPCs and of SYN1 in neurons derived from Twin-DS-iPSCs. Moreover, recent studies point to an important role of DYRK1A in dendrites tree development, synapse formation and function (Tejedor & Hämmerle, 2011; Martinez de Lagran et al., 2012). For instance, single overexpression of Dyrk1A in vivo is sufficient to recapitulate the dendritic alterations observed in DS patients (Martinez de Lagran et al., 2012). In line with this, we found that DYRK1A inhibition by EGCG or by shRNA promotes the dendritic development of neurons derived from Twin-DS-iPSCs. This effect was associated with a restoration of the expression to near normal levels of WNT7A, WNT7B, NOTCH1, NOTCH2, DLL1 and HES1. This is of special interest as these genes are crucial regulators of dendrite morphogenesis and synapse assembly (Ciani & Salinas, 2005; Breunig et al., 2007; Ables et al., 2011) and could explain at least in part, the defects in dendritic development due to DYRK1A overexpression in the present study and recent reports (Gued et al., 2009; Tejedor & Hämmerle, 2011; Martinez de Lagran et al., 2012). Of note, when NPCs derived from Twin-DS-iPSCs were treated with EGCG during neuronal differentiation only (and not before, during neural induction), no improvement in the number of neurons was found. However, this delayed targeting of DYRK1A by EGCG promoted dendritic development and the density of the synaptic protein SYNAPSSIN in these neurons (supplementary Fig S10). These results further highlight the pleiotropic roles of DYRK1A during the sequential stages of neural induction and neuronal differentiation of iPSCs as well as the potential opportunities for DS therapy through DYRK1A targeting in early and late neurodevelopmental events.

In conclusion, the generation of iPSCs from monozygotic twins discordant for trisomy 21 provides a unique model to study the effects of trisomy 21 of two otherwise genetically identical samples (Dahoun et al., 2008). This model recapitulates neurodevelopmental features of DS and provides important clues to the physiopathology of the disease (supplementary Fig S11). Our study further emphasizes DYRK1A as a main contributor of neurogenesis impairment in NPCs and neurons derived from Twin-DS-iPSCs and provides novel insights into the therapeutic potential of DYRK1A targeting in patients with DS. It is important to note, however, that other genes including OLG1, NOTCH and WNT deserve further investigation. Finally, the finding that DYRK1A inhibition by pharmacological and genetic approaches contributes to reverse the abnormal neurogenesis in NPCs and neurons derived from Twin-DS-iPSCs, allows a proof-of-principle for potential screening tests using iPSC technology (Hibaoui & Feki, 2012) and should provide the basis for designing new therapeutic approaches for patients with DS.

Materials and Methods

Cell culture and iPSC derivation

Primary fetal skin fibroblasts were isolated from monozygotic twins discordant for trisomy 21 (Twin-N for the normal fibroblasts and Twin-DS for the trisomy 21) and used to establish normal (Twin-N-iPSCs) and Down syndrome (Twin-DS-iPSCs) induced pluripotent stem cells (iPSCs). These samples were obtained post mortem and the study was approved by the ethics committee of the Geneva University Hospital. These iPSCs were generated by transducing the parental fibroblasts (Twin-N and Twin-DS) with polycistronic lentiviral vectors expressing OCT4, SOX2, KLF4 and c-MYC genes (Takahashi et al., 2007; Grad et al., 2011). Colonies that appeared were isolated and expanded into lines (see also supplementary Table S1). H1-hESCs (obtained from WiCell Research Institute, Madison, WI, USA) and the generated iPSCs were cultured on irradiated human foreskin fibroblasts (ATCC; CCD 1112Sk, Manassas, VA, USA) that were mitotically inactivated by irradiation at 35 Gy before seeding on a gelatin-coated 6-well plate at 3.5 × 10^5 cells/plate. iPSC colonies were maintained with daily changes in Knock-out Dulbecco’s Minimal Essential Medium (KO DMEM) supplemented with 20% KO serum replacement, 1 mM L-glutamine, 100 μM non-essential amino acids, 100 μM 2-mercaptoethanol, 50 U/ml penicillin and 50 mg/ml streptomycin (all from Gibco, Invitrogen, Basel, Switzerland) and 100 ng/ml human basic fibroblast growth factor (bFGF; Peprotech, London, UK). All iPSC lines were passaged by manual dissection of cell clusters in the presence of 10 μM ROCK-inhibitor Y-27632 (Sigma-Aldrich, Buhs, Switzerland).

Spontaneous in vitro three-germ layer differentiation

Whole iPSC colonies were seeded into ultra low attachment dishes (Costar; Corning Life Sciences, Schiphol-Rijk, The Netherlands) in KO DMEM medium supplemented with 10% new calf serum, 1 mM L-glutamine, 100 μM non-essential amino acids, 100 μM 2-mercaptoethanol, 50 U/ml penicillin and 50 mg/ml streptomycin. Within 24 h, cells aggregated to form embryoid bodies (EBs). After 4 days growing in suspension, these EBs were transferred to gelatin-coated dishes containing the same medium to allow the cells to differentiate for an additional 17 days.

Neural induction of iPSCs into NPCs and neuronal differentiation into neurons

Differentialiation of iPSCs into neural progenitor cells (NPCs) and mature neurons was established as described with minor modifications (Suter et al., 2009; Brennand et al., 2011). Briefly, the colonies were mechanically detached from the feeder cells, washed and maintained in suspension in ultra-low attachment dishes (Costar, Corning Life Sciences) for 1 week in neural induction medium (NIM) consisting of DMEM-F12, 1% penicillin/streptomycin, N2 supplement (Gibco, Invitrogen) and replaced with NIM supplemented with 10 ng/ml human recombinant bFGF for another 2 weeks. Thereafter, NPCs were further induced to mature into neurons by plating the dissociated aggregates on poly-ornithine/laminin-coated tissue culture plate in neural differentiation medium (NDM) consisting of neurobasal supplemented with B-27 supplement (Gibco, Invitrogen), 10 ng/ml BDNF (R&D Systems, Inc., Minneapolis, MN, USA), 10 ng/ml GDNF (R&D Systems, Inc.), 1 mM dibutyryl-cyclic AMP, 200 nM ascorbic acid (Sigma-Aldrich, Buhs) and 1% penicillin/streptomycin for 4 weeks. Medium was changed every 3 days.

Teratoma formation from iPSCs

All the procedures involving animals were conducted in accordance with the Swiss Federal Veterinary Office’s guidelines, based on the Swiss Federal Law on Animal Welfare. In vivo differentiation studies
were carried out by teratoma formation. 5 × 10^6 cells from each iPSCs were harvested and injected intramuscularly into SCID mice. After 8 weeks, the teratomas were excised, fixed in 4% formaldehyde, and embedded in paraffin for hematoxylin and eosin (HE) staining or for immunohistochemistry analysis with horseradish peroxidase system. 4 μm thick teratomas sections from formalin fixed paraffin embedded samples were analyzed by immunohistochemistry using anti-alpha-fetoprotein (NCL-AFPp, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), anti-alpha-smooth muscle actin (M0851, Dako, Baar, Switzerland) and anti-nestin antibodies (MAB1259, R&D systems, Inc.) with the Ventana Discovery automated staining system (Ventana Medical Systems, Tucson, AZ, USA). Ventana reagents for the entire procedure were used. For both AML and AFP antibodies, no antigen retrieval pretreatment was required. After automatic deparaffinization, slides were incubated 30 min at 37°C with primary antibodies respectively diluted at 1/300 (AML) and 1/750 (AFP) in antibody diluent from Dako (S2022). For nestin antigen retrieval, slides were heated in CC1 cell conditioning solution for 36 min (EDTA antigen retrieval solution pH 8.4) using a standard protocol. Anti-nestin antibodies were used at dilution 1/1000 and also incubated 30 min at 37°C. Detection of primary antibodies was carried out using the secondary universal biotinylated antibodies reagent and the amplified DABMap kit (Ventana Medical Systems), based on conversion of diaminobenzidine to a dye with multimeric horseradish peroxidase (HRP). As negative control, AFP antibodies were replaced by rabbit control immunoglobulins and AML and nestin antibodies were replaced by mouse IgG serotype control.

**Immunocytochemistry**

Briefly, iPSCs at different stages of neuronal differentiation were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) for 30 min, permeabilized with 0.2% Triton X-100 for 30 min, and blocked with 5% bovine serum albumin in PBS for 1 h at room temperature (RT). Cells were incubated with primary antibody overnight at 4°C, washed with PBS and incubated with secondary antibody for 1 h at RT. All secondary antibodies were tested for crossreactivity and nonspecific immunoreactivity. The antibodies used for immunohistochemical staining are listed in supplementary Table S4. The cells were finally mounted in UltraCruz™ mounting medium containing DAPI for nuclei identification (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Images of the immunostained cells were captured on a Zeiss Axioskop 2 fluorescence microscope with an Axiocam Color HRc detector (Zeiss, Feldbach, Switzerland). Staining of cells derived from Twin-N-iPSCs and Twin-DS-iPSCs, neurite length and number were analyzed with ImageJ software. N values for the immunocytochemical analyses represent at least four independent experiments in triplicate.

**Karyotype analysis**

Karyotyping was performed on at least twenty metaphase spreads using the CTG-banding method. iPSCs at 80% confluence were treated with 0.2 μg/ml colcemid (Invitrogen) for 2 h and harvested. Cell pellets were resuspended in pre-warmed hypotonic solution (KCl, 0.075 mol/l) for 10 min at 37°C. Cells were then fixed with freshly prepared, ice-cold methanol-acetic acid solution (3:1 in volume) and mounted by dropping onto slides.

**Bisulfite sequencing analysis**

About 2 μg of DNA extracted from the iPSCs and the parental fibroblasts were bisulfite-converted and purified using Epitect Bisulfite Kits (Qiagen, Valencia CA, USA) following the manufacturer’s instruction. DNA bisulphite treatment and processing were performed simultaneously for all cell lines. The promoter regions of OCT4 and NANOG were amplified with specific primers previously described (Freberg et al., 2007) using JumpStart REDTaq DNA Polymerase (Sigma-Aldrich, Buhs) and KAPA2G Robust DNA Polymerase (Kapabiosystems, Boston, MA, USA). Quantitative methylation percentages were determined by Epitect sequencing (QUAGEN GmbH, Hilden, Germany). The Epitect sequencing service includes sequencing of the PCR products using cycle sequencing (Reactions were cycled in a GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA, USA) and purified using DyeEx™ (QIAGEN). Data collection was carried out on a 3730xl DNA Analyzer (Applied Biosystems). It also includes modified analysis of raw data to obtain a percentage of methylation for each CpG dinucleotide. The methylation percentages of these sites were averaged to obtain a single methylation score for each sample.

**Array CGH**

Array-Comparative Genomic Hybridization (CGH) was performed using the Human Genome CGH Microarray Kit 44A (Agilent Technologies, Palo Alto, CA, USA) with a resolution of about 150 kb. Briefly, 1 μg of iPS DNA was processed according to the manufacturer’s protocol. Fluorescence was scanned in a dual-laser scanner (Agilent DNA microarray scanner G2565CA; Agilent Technologies) and the images were extracted and analysed with Agilent Feature Extraction software (v9.5.3.1) and Workbench analysis software (v7.0) respectively. Changes in test DNA copy number at a specific locus are observed as the deviation of the log ratio value from a modal value of 0. The data files have been deposited in the Gene Expression Omnibus (GEO) database under the accession number GSE52251 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52251).

**RNA extraction, non-quantitative and quantitative real time polymerase chain reaction**

Total RNA was extracted from the cell lines, using the QIAGEN RNeasy MiniKit according to the manufacturer’s protocol (Invitrogen). RNA integrity and quantity were assessed with an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), using RNA 6000 nanochips. 1 μg of total RNAs were reverse transcribed with the Superscript III reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. One-twentieth cDNA template was used as template for each PCR reaction. cDNA was real time polymerase chain (PCR) amplified in a 7900HT Sequence Detection Systems (Applied Biosystems) using the Power SYBR Green PCR master mix (Applied Biosystems). Raw threshold-cycle (Ct) values were obtained with the Sequence Detection Systems 2.0 software (Applied Biosystems). Melting curve analysis were auto-
matically performed to monitor production of the appropriate PCR product. Relative quantities (RQs) were calculated with the formula RQ = E–Ct, using efficiencies calculated for each run with the Data Analysis for Real-Time PCR (DART-PCR) algorithm, as described (Peirson et al., 2003). A mean quantity was calculated from triplicate PCR reactions for each sample, and this quantity was normalized against that of the housekeeping genes (GusB and eEF1). Each PCR reaction was performed at least in triplicate with negative controls and the mean quantities were calculated from them. For non-quantitative PCR, reactions were performed in a Biometra thermocycler (Göttingen, Germany), with RedTaq polymerase mix (Sigma-Aldrich, St. Louis, MO, USA), 250 nM primers and 1 µl of cDNA. The primer sequences used for quantitative and non-quantitative RT-PCR are listed in supplementary Table S4.

Gene expression analysis by mRNA sequencing

mRNA-Seq libraries were prepared from 500 ng of total RNA using the Illumina TruSeq™ RNA Sample Preparation kit (S-930-2001, Illumina, Inc., San Diego, CA, USA), following the manufacturer’s instructions. Libraries were sequenced on the Illumina HiSeq 2000 instrument (Illumina, Inc.) to generate 100 bp paired-end reads. Those reads were mapped against the genome (hg 19) using the default parameters of the Burrows-Wheeler Aligner (BWA; Li & Durbin, 2009). An expression signal was detected in at least one sample for 20'456 genes (comprising also non-coding RNA). For each gene, the level of expression was determined by calculating the exon coverage (custom pipeline) and normalizing in Reads per Kilobase per Million (RPKM). Twin-DS-iPSC and Twin-N-iPSC samples were sequenced in three and four biological replicates, respectively, starting from different RNA preparations. Principal component analyses (PCA) and clustering analyses were performed using R (version 2.14.0, http://www.R-project.org/). Differential expression between the trisomic and the normal replicates was assessed using the Data Analysis for Real-Time PCR (DART-PCR) algorithm, as described (Birren et al., 2003). A mean quantity was calculated from triplicate PCR reactions for each sample, and this quantity was normalized against that of the housekeeping genes (GusB and eEF1). Each PCR reaction was performed at least in triplicate with negative controls and the mean quantities were calculated from them. For non-quantitative PCR, reactions were performed in a Biometra thermocycler (Göttingen, Germany), with RedTaq polymerase mix (Sigma-Aldrich, St. Louis, MO, USA), 250 nM primers and 1 µl of cDNA. The primer sequences used for quantitative and non-quantitative RT-PCR are listed in supplementary Table S4.

**DYRK1A kinase assay**

NPCs were lysed by up-and-down pipetting with a lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 15% glycerol, 1 mM EDTA, 1 mM NaF, 1 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml pepstatin, 10 µg/ml leupeptin, 1 µl PMSF). After centrifugation (21 000 g, 4°C, 10 min), the supernatant was stored at −80°C. DYRK1A immunoprecipitation was performed using a monoclonal anti-DYRK1A (clone 7D10; Abnova, Taipei City, Taiwan) as previously described with slight modifications (Lilienthal et al., 2010). In vitro DYRK1A kinase activity was measured by incubating the immunoprecipitated DYRK1A with the substrate peptide DYRKtide (Catalog#62698; Anaspec, Fremont, CA, USA) in a kinase buffer (25 mM Hepes pH 7.0, 5 mM MgCl2 and 0.5 mM dithiothreitol) containing 40 µM ATP for 3 h at 37°C. DYRK1A kinase activity was measured by quantifying the amount of remaining ATP in the reaction using kinase-Glo luminescent reagent (Promega, Dübendorf, Switzerland). Luminescence was monitored in a plate reader luminometer (Fluostar Optima; BMG Labtechnologies, Offenburg, Germany).

**DYRK1A knockdown assay and DYRK1A inhibition with epigallocatechine gallate**

Knockdown of DYRK1A was achieved by means of lentiviral vector-mediated short hairpin RNA (shRNA), using validated commercial lentiviral particles for the DYRK1A sequence (Sigma-Aldrich, Buhs). For viral transduction, Twin-DS-iPSCs were plated on matrigel-coated dishes and infected at a multiplicity of infection of 30 in the presence of 10 µg/ml polybrene. As controls, Twin-N-iPSCs and Twin-DS-iPSCs were also infected with control shRNA. Knockdown efficiencies of DYRK1A targeted shRNA were evaluated by real-time RT-PCR and by Western blotting analysis. Moreover, to test the effect of pharmacological DYRK1A inhibition on neurogenesis, Twin-DS-iPSCs were treated with the selective DYRK1A inhibitor epigallocatechine gallate EGCG (Sigma-Aldrich, Buhs) at a concentration of 10 µM in NIM and NDM with medium changes every 2 days. All comparative differentiation experiments were carried out with all experimental lines and controls in parallel.
**The paper explained**

**Problem**
Down syndrome (DS) caused by a trisomy of chromosome 21 (HSA21), is the most common genetic developmental disorder, with an incidence of one in 800 live births. DS individuals show intellectual impairment and several other abnormalities for the majority of which the pathogenetic mechanisms remain unknown. A major challenge has been to recapitulate the disease features and to understand the molecular mechanisms by which the extra copy of HSA21 genes leads to the abnormalities observed in DS patients. Recent studies have been successful in generating disease-specific induced pluripotent stem cells (iPSCs) from a variety of neurodevelopmental and neurodegenerative disorders, providing useful in vitro models.

**Results**
We report the generation and characterization of iPSCs derived from monozygotic twins discordant for trisomy 21 in order to eliminate the effects of the variability of the genomic background. This provides a unique model to study the effect of the supernumerary HSA21 since the rest of the genome is identical between the two twins. DS iPSCs recapitulate the neurodevelopmental features of DS. First, the alterations observed by genetic analysis at the iPS level and at first approximation in early development illustrate the developmental disease transcriptional signature of DS. Then, in vivo differentiation of DS iPSCs revealed an abnormal teratoma formation in NOD-SCID mice. In vitro, we found a reduced neurogenesis together with a greater astroglial and oligodendroglial cell population upon neural induction into neural progenitor cells (NPCs) and upon neuronal differentiation of DS iPSCs. This effect was associated with a proliferation deficit and increased apoptosis of NPCs derived from DS iPSCs. In addition, neurons derived from DS iPSCs showed reduced dendritic development and expression of synaptic proteins. Importantly, we provide novel evidence that DYRK1A on HSA21 likely contributes to these defects as its inhibition by pharmacological means or by short hairpin RNA silencing corrected these defects. We found that this correction improved proliferation, decreased apoptosis of NPCs and increased the number of neurons derived from DS iPSCs. Also, DYRK1A correction was associated with the restoration of the expression to near normal levels of crucial regulators of neurogenesis and dendritic development including REST/NRSF, WNT and NOTCH signalling.

**Impact**
The generation of iPSCs from monozygotic twins discordant for trisomy 21 is an innovative way to study DS neurodevelopment as it offers an unprecedented opportunity to study early embryonic development and enables the investigation of the detailed pathogenetic mechanisms by which the extra copy of HSA21 leads to DS phenotypes. The finding that DYRK1A inhibition by pharmacological and genetic approaches contributes to reversal of the abnormal neurogenesis in NPCs and neurons derived from DS iPSCs, allows a proof-of-principle for potential screening tests using iPSC technology and should provide the basis for designing new therapeutic approaches for DS patients.

**Western blotting**
NPCs were solubilized at 4°C in 100 μl of lysis buffer and centrifuged to remove debris. Protein were resolved in 7.5% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Incubation with anti-DYRK1A antibody was carried out overnight at 4°C using dilutions of 1:1000 (clone 7D10; Abnova). After incubation with HRP-conjugated secondary antibodies during 1 h, membranes were developed by enhanced chemiluminescence reagents (ECL reagent; Amersham Biosciences) according to the manufacturer’s instructions. Signals were quantified and normalized to α-tubulin (clone DM1A T9026; Sigma, Buhs) and expressed as arbitrary units.

**Data analysis**
The data were analyzed and the graphs were constructed using the GraphPad Prism software (GraphPad, San Diego, CA, USA). Data are shown as mean ± s.e.m. Statistical analysis among groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test, and comparisons between two groups by Student’s t-test. P values of <0.05 were considered significant.

**Supplementary information** for is this article available online: www.embommm.embopress.org

**Acknowledgements**
This work was supported by grants from the Ernest Boninchi Fondation to A.F., Genico to A.F., the Swiss National Science Foundation (SNF) to S.E.A. and the European Research Council (ERC) to S.E.A. We are grateful to S. Vianin and L. Kocijancic-Curty for their technical support.

**Author contributions**
YH performed the majority of the experiments and analyzed the data. IG, AL, MRS, SD, MG, and SG performed the experiments. IG, AL, FAS, MFP and FB analyzed the data. YH, SEA and AF conceived and designed the study and wrote the manuscript. AF and SEA supervised whole study.

**Conflict of interest**
The authors declare that they have no conflict of interest.

**References**


